|Ovarin cancer drugs show promise for Amgen and Takeda|
|By BioMedReports.com Staff|
|Friday, 08 October 2010 18:35|
An experimental drug being developed by Amgen, Inc.(NASDAQ:AMGN) found that it can extend survival for women with advanced ovarian cancer when combined with chemotherapy.Amgen said it has begun a Phase 3 of the drug, in combination with paclitaxel, as a treatment for ovarian, primary peritoneal, and fallopian tube cancers.
Another experimental ovarian cancer drug, this one from from Japanese drugmaker Takeda Pharmaceutical (PINK:TKPYY), helped some difficult-to-treat patients in a small trial. The results are pushing the case for more research on the compound. The new oral treatment, called MLN8237, was acquired by Tekeda after buying U.S. biotech firm Millennium Pharmaceuticals in 2008. The move was part of a drive to boost its cancer pipeline and raise its U.S. exposure.
Below is a look at some of the headlines for companies that made news in the healthcare sector on October 08, 2010.
Abbott (NYSE:ABT) today was named one of the top 20 employers in Science magazine's 2010 Top Biopharma Employers survey.
ADVENTRX Pharmaceuticals, Inc. (NYSE Amex:ANX) will participate in PrecisionIR's Informed Investors Forum Biotech, Healthcare & Pharma Virtual Conference.
The Amergence Group (PINKSHEETS:AMNG), a company that focuses on developing, nurturing, and rapidly expanding selected emerging or "disruptive" companies across a wide range of industries and disciplines, announced today that it has completed the successful acquisition of Altitude Organic Licensing Corporation (AO) which is headquartered in Denver, Colorado.
AmerisourceBergen Corporation (NYSE:ABC) today announced that it plans to release its results for the 2010 Fiscal Fourth Quarter and Year End on Tuesday, November 2, 2010 prior to the opening of trading on the New York Stock Exchange.
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company presented new pre-clinical research today at the 8th International M. Judah Forkman Conference, New Frontiers in Therapeutic Development, held October 8-9, 2010 in Cambridge, Mass, highlighting significant advances in the systemic delivery of RNAi therapeutics.
Apricus Biosciences (“Apricus Bio”) (Nasdaq: APRI), backed by a revenue generating CRO business and seeking to leverage its multi-route NexACT® drug delivery technology and internal pipeline through out-licensing partnerships, today announced that the Company is featured as a special stock pick in the October 2010 issue of the KonLin Letter, an independent New York-based investment newsletter (www.konlin.com) published by KonLin Research & Analysis.
Bacterin International Holdings, Inc. (OTC Bulletin Board:BIHI) ("Bacterin"), today announced Guy Cook, President & CEO of Bacterin will be presenting at the 6th Annual Fall Growth Stock Conference hosted by Security Research Associates, Inc. ("SRA").
Bio-Clean, Inc. (OTCBB: BOCL) is pleased to announce that it has changed its name to Global NuTech, Inc.
Bristol-Myers Squibb Company (NYSE: BMY) announced today that the tender offer, through its wholly owned subsidiary Zeus Acquisition Corporation, for all outstanding shares of common stock of ZymoGenetics, Inc. (NASDAQ: ZGEN) expired at midnight New York City time on October 7, 2010, and was not extended.
Caraco Pharmaceutical Laboratories, Ltd. (NYSE Amex:CPD) announced today that G. P. Singh Sachdeva will assume the position of Chief Executive Officer following the resignation of Jitendra N. Doshi as interim Chief Executive Officer and as a Director, effective November 1, 2010, due to personal and health-related reasons.
CVS Caremark (NYSE:CVS) is leading the private-sector effort to address health care cost and quality issues, with several recently introduced initiatives now set to deliver long-term value, Chairman and CEO Tom Ryan, President and Chief Operating Officer Larry Merlo and other senior executives will report at the company's 2010 analyst meeting in New York City today.
Cypress Bioscience, Inc. (NASDAQ:CYPB), a pharmaceutical company engaged in the development of innovative drugs to treat central nervous system (CNS) disorders, today announced that it has entered into an asset purchase agreement under which Exagen Diagnostics, Inc. will acquire Cypress' diagnostic business for a total of up to $8 million in upfront and milestone payments, with additional future payments in the form of royalties on product sales.
Cytori Therapeutics (NASDAQ: CYTX) is selling 4,000,000 shares of its common stock at a price to the public of $4.50 per share. The net proceeds from the sale of the shares, after underwriting discounts and commissions and other offering expenses, are expected to be approximately $16.8 million.
Genzyme Corp. (NASDAQ: GENZ) announced today that its board of directors has voted unanimously to reject the unsolicited $69.00 per share tender offer from Sanofi-Aventis, and the board recommends that Genzyme shareholders not tender their shares to Sanofi-Aventis pursuant to the offer.
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted antibody-based anticancer products, today announced the reporting of positive interim clinical data with trastuzumab-DM1 (T-DM1) for first-line treatment of HER2+ metastatic breast cancer in a press release issued by the European Society for Medical Oncology (ESMO).
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced the appointment of Sunil Patel to the Company's Board of Directors.
MMRGlobal, Inc. (OTCBB:MMRF) (the "Company") today announced that David A. Boyden, a member of MMRGlobal's Board of Directors (the "Board") since January 2009, has notified the Company of his intent to resign from the Board, effective today.
Molecular Insight Pharmaceuticals, Inc. (NASDAQ:MIPI), a biopharmaceutical company discovering and developing targeted therapeutic and imaging radiopharmaceuticals for use in oncology, announced that the Company has received two letters from The NASDAQ Stock Market regarding deficiencies relating to NASDAQ Rules.
Proteonomix, Inc. (OTCBB: PROT) ("Proteonomix" or the "Company") announced today that it has filed a utility patent application for the Preparation and Use of Stromal Cells for Treatment of Cardiac Diseases.
Regeneron Pharmaceuticals, Inc. (Nasdaq:REGN) today announced that it has increased the size of its previously announced underwritten public offering of Common Stock from 4,500,000 shares to 5,500,000 shares and agreed to an indicative price of $28.00 per share for the offering. Citi is serving as sole book-running manager for the offering.
Ken Glynn, President of SpeechSwitch, Inc. (PINKSHEETS:SSWC), reported today that another of the required SEC documents to bring the company current was submitted today for EDGAR review.
Unity Management Group, Inc. (PINKSHEETS:UYMG), a Health Resource Company specializing in Physician and Hospital Practice Management, Medical Discount Plans, Business Services, Billing Software and Technologies.
Walgreens (NYSE: WAG) (NASDAQ: WAG) continues its commitment to fostering diversity in the field of pharmacy with a $1.1 million donation to accredited pharmacy schools around the country.
XTend Medical, (PINKSHEETS: XTDC), a company that specializes in delivering life changing medical technology to healthcare organizations globally, has informed Pink Sheets that our status as an ongoing company with operations has not changed since August of 2007.